You are here

  • Home
  • Archive
  • Volume 14, Issue 3
  • First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment

Article info

Article menu

Download PDFPDF

XML
Case report
First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment

Authors

  • Hata Karamujić-Čomić Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsNational Prion Disease Registry, Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Annemieke J M Rozemuller Department of Pathology, Amsterdam Neuroscience, Amsterdam UMC, VU University Medical Center, Amsterdam, The NetherlandsDepartment of Pathology, UMC Utrecht, Utrecht, The Netherlands PubMed articlesGoogle scholar articles
  • M Arfan Ikram Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsNational Prion Disease Registry, Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Cornelia M van Duijn Department of Epidemiology, Erasmus MC, University Medical Center, Rotterdam, The NetherlandsClinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Hata Karamujić-Čomić; h.comic{at}erasmusmc.nl
View Full Text

Citation

Karamujić-Čomić H, Rozemuller AJM, Ikram MA, et al
First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment
BMJ Case Reports CP 2021;14:e235509.

Publication history

  • Accepted January 27, 2021
  • First published March 29, 2021.
Online issue publication 
January 24, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© BMJ Publishing Group Limited 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.